Euclises Pharmaceuticals
PrivateLast Round
Series A
Extension
Apr 7, 2015
Total Funding Raised
$3.48M
Company Overview
Euclises Pharmaceuticals operates in Healthcare & Life Sciences and is based in Saint Louis, Michigan. Its latest recorded funding round was a Series A Extension round in April 2015.
Euclises Pharmaceuticals is a biotechnology company that develops novel COX-2 inhibitors for the treatment of oncology patients.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Euclises Pharmaceuticals Comparables
Compare Euclises Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Owkin | 73% | |
| Yiviva | 71% | |
| Kainova Therapeutics | 70% |
For institutional investors. Book with your work email.
Euclises Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Apr 7, 2015 | ||||
| Series A | Sep 9, 2014 | ||||
| Seed | Jun 11, 2012 |
For institutional investors. Book with your work email.
Euclises Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cultivation Capital | Series A Extension, Series A |
| Missouri Technology Corporation | Series A |
| St. Louis Arch Angels | Series A Extension, Seed, Series A |
| BioGenerator Ventures | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 24, 2024
Monthly visitors increased 60% MoM.
- Apr 7, 2015
$2M round with BioGenerator Ventures and Cultivation Capital.
For institutional investors. Book with your work email.
Euclises Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Euclises Pharmaceuticals's valuation, stock price, and market status.
Is Euclises Pharmaceuticals a public or private company?
Euclises Pharmaceuticals is a private company.
What is the current stock price of Euclises Pharmaceuticals?
Euclises Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Euclises Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Euclises Pharmaceuticals worth (valuation)?
Valuation information for Euclises Pharmaceuticals is not publicly available.
Can I buy Euclises Pharmaceuticals stock?
Euclises Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Euclises Pharmaceuticals's last funding round?
Euclises Pharmaceuticals's most recent funding round was Series A Extension on April 7, 2015.
Who are the main investors in Euclises Pharmaceuticals?
Key investors in Euclises Pharmaceuticals include Cultivation Capital.
Will Euclises Pharmaceuticals IPO soon?
No public IPO plans have been announced for Euclises Pharmaceuticals.
How can I track Euclises Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Euclises Pharmaceuticals's shares on secondary markets.